Qiming Healthcare — Full Portfolio
10 tracked investments · listed companies and verified rows first
HealthtechSan Mateo, US
Victor Colunga(Executive Officer)Stephen G. Dilly, Jr.(Executive Officer, Director)
BoardJoonkyoo (Anthony) Yun(Director)Stacey D. Seltzer(Director)James Tananbaum(Director)Patrick Enright(Director)
Board seatMark D. McDade· per SEC Form D · $98M raise · filed Nov 2018
Co-investorsForesite Capital
BiotechSan Francisco, US
Jeanmarie Guenot(Executive Officer, Director)Florian Fischer(Director)
BoardLuke Evnin(Director)in
Board seatMark McDade· per SEC Form D · $50M raise · filed Dec 2018
Co-investorsMPM BioImpact
Portland, US
Board seatMark McDade· per SEC Form D · $41.6M raise · filed May 2022
Co-investorsFirst Round CapitalTusk Venture Partners
HealthtechMenlo Park, US
THOMAS G. WIGGANS(Executive Officer, Director)EUGENE A. BAUER(Executive Officer, Director)ANDREW GUGGENHIME(Executive Officer)LUIS PENA(Executive Officer)CHRISTOPHER GRIFFITH(Executive Officer)David E. Cohen(Director)
Board seatMark D. McDadeMark McDade· per SEC Form D · $1M raise · filed Dec 2018
Co-investorsAisling CapitalBay City CapitalCanaan PartnersForesite CapitalNew Enterprise Associates (NEA)Fidelity Investments+1 more
Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations.
BiotechDeep TechSouth San Francisco, US
Forbes Huang(Co-Founder, Chief Operating Officer & Chief Business Officer)Greg Lazar(Co-Founder & Chief Scientific Officer)Richard Murray(Executive Officer, Director)Karim Dabbagh(Chief Executive Officer, Board Member)
BoardAlicia Levey(Director)Michael Ross(Director)
Board seatMark McDade· per SEC Form D · $66.6M raise · filed Nov 2025
Co-investorsQiming Venture PartnersSV Health InvestorsVersant VenturesDementia Discovery Fund
BiotechSeattle, US
Charles Richardson(Senior Vice President, Technical Operations)Adam K. Simpson(President and Chief Executive Officer)Niranjan Kanesa-thasan(Chief Medical Officer)Douglas A. Holtzman(Chief Scientific Officer and Secretary)Cassia Cearley(Treasurer, Chief Business Officer)
BoardPeter Kolchinsky(Director)in
Board seatMark McDade· per SEC Form D · $51M raise · filed Oct 2019
Co-investorsRA CapitalSanofi Ventures
BiotechChestnut Hill, US
Joseph Italiano(Director)Jonathan Thon(Director)Sven Erik Karlsson(Executive Officer)Peter Finn(Executive Officer)
Board seatMark McDade· per SEC Form D · $26.4M raise · filed Aug 2019
Co-investorsBoston Harbor AngelsThird Rock Ventures
Chicago, US
Robert Alan Knight(Executive Officer, Director)Christopher Elliot Brown(Executive Officer)Jared Dauman(Executive Officer)James Daryl Risinger(Executive Officer, Director)
BoardCaitlin Donovan(Director)Galym Imanbayev(Director)in
Board seatMark McDade· per SEC Form D · $54.2M raise · filed Dec 2024
Co-investorsDefine VenturesLightspeed Venture Partners
BiotechLouisville, US
Suzanne Ildstad(Executive Officer, Director)Scott Requadt(Executive Officer, Director)Geoff Mackay(Director)Francois Nader(Director)
BoardSandip Agarwala(Director)
Board seatMark McDade· per SEC Form D · $115M raise · filed Oct 2020
WindMIL Therapeutics is a clinical-stage biotechnology company developing cell-based immuno-oncology therapies using marrow-infiltrating lymphocytes (MILs), T cells extracted from a cancer patient's bone marrow that are activated and expanded before being returned to the patient.
BiotechMedical DevicesPrinceton, US
Ivan Borrello(Founder)Kimberly Noonan(Founder)
BoardBrian Halak(Executive Officer, Director)
Board seatAnna FrenchMark McDade· per SEC Form D · $5M raise · filed Feb 2021
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.